Vertex announces advancements of Suzetrigine in acute and neuropathic pain
Breakthrough Therapy designation for pain associated with DPN granted by FDA
Breakthrough Therapy designation for pain associated with DPN granted by FDA
Submission based on results from pivotal phase III trial showing all primary endpoints met
Ofloxacin Ophthalmic Solution USP 0.3% is indicated for treatment of eye infections caused during the conditions of conjunctivitis and corneal ulcers
NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
This facility manufactures APIs & formulations of oncology and non-oncology products.
The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
The company will respond to the Warning Letter within the stipulated timelines
Subscribe To Our Newsletter & Stay Updated